Our comprehensive investigation into the pathophysiology of androgenic alopecia has revealed a range of complex mechanisms contributing to hair loss and thinning. In response, we focused on the development of targeted molecules designed to address each of these mechanisms individually. Each molecule underwent extensive preclinical and clinical testing to confirm both efficacy and safety, with the results published in 2024.

A human clinical trial, conducted with rigorous controls, demonstrated a statistically significant increase in hair count when compared to the placebo group.

TrinogeniX™, a proprietary blend of three patented ingredients, offers a scientifically backed solution that delivers tangible and lasting results.

2022~2024

• Human clinical trial

2021~2022

• in-vivo / ex-vivo efficacy evaluation

2021

• Target molecule development
• Disease MoA (Mechanism of Action) identification